← Back to Search

Virus Therapy

HCVax for Chronic Hepatitis C

Phase 1
Waitlist Available
Research Sponsored by GeneCure Biotechnologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new vaccine called HCVax™ that uses a special virus to help the immune system fight Hepatitis C. It is aimed at patients who have long-term Hepatitis C infections. The vaccine works by teaching the immune system to recognize and attack the Hepatitis C virus.

Eligible Conditions
  • Chronic Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 40 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the safety of a therapeutic HCV vaccine in chronic HCV patients
Secondary study objectives
To evaluate the immunogenicity of a therapeutic HCV vaccine in chronic HCV patients
Virologic response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low dose groupExperimental Treatment1 Intervention
Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
Group II: High dose groupExperimental Treatment1 Intervention
Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.

Find a Location

Who is running the clinical trial?

GeneCure BiotechnologiesLead Sponsor
2 Previous Clinical Trials
62 Total Patients Enrolled

Media Library

HCVax (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04318379 — Phase 1
Chronic Hepatitis C Research Study Groups: Low dose group, High dose group
Chronic Hepatitis C Clinical Trial 2023: HCVax Highlights & Side Effects. Trial Name: NCT04318379 — Phase 1
HCVax (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04318379 — Phase 1
~7 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top